Abstract
Glycogen storage disease type 1 (GSD1) is a rare hereditary monogenic disease characterized by the disturbed glucose metabolism. The most widespread variant of GSD1 is GSD1a, which is a deficiency of glucose-6-phosphatase-ɑ. Glucose-6-phosphatase-ɑ is expressed only in liver, kidney, and intestine, and these organs are primarily affected by its deficiency, and long-term complications of GSD1a include hepatic tumors and chronic liver disease. This article is a brief overview of existing animal models for GSD1a, from the first mouse model of 1996 to modern CRISPR/Cas9-generated ones. First whole-body murine models demonstrated exact metabolic symptoms of GSD1a, but the animals did not survive weaning. The protocol for glucose treatment allowed prolonged survival of affected animals, but long-term complications, such as hepatic tumorigenesis, could not be investigated. Next, organ-specific knockout models were developed, and most of the metabolic research was performed on liver glucose-6-phosphate-deficient mice. Naturally occuring mutation was also discovered in dogs. All these models are widely used to study GSD1a from metabolic and physiological standpoints and to develop possible treatments involving gene therapy. Research performed using these models helped elucidate the role of glycogen and lipid accumulation, hypoxia, mitochondrial dysfunction, and autophagy impairment in long-term complications of GSD1a, including hepatic tumorigenesis. Recently, gene replacement therapy and genome editing were tested on described models, and some of the developed approaches have reached clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdul-Wahed A, Gautier-Stein A, Casteras S et al (2014) A link between hepatic glucose production and peripheral energy metabolism via hepatokines. Mol Metab 3:531–543. https://doi.org/10.1016/j.molmet.2014.05.005
Airley RE, McHugh P, Evans AR et al (2014) Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression. Br J Cancer 110:715–723. https://doi.org/10.1038/bjc.2013.765
Akinc A, Querbes W, De S et al (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18:1357–1364. https://doi.org/10.1038/mt.2010.85
Arnaoutova I, Zhang L, Chen HD et al (2021) Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing. Mol Ther 29:1602–1610. https://doi.org/10.1016/j.ymthe.2020.12.027
Beaty RM, Jackson M, Peterson D et al (2002) Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type la, with adeno-associated virus (AAV) vectors. Gene Ther 9:1015–1022. https://doi.org/10.1038/sj.gt.3301728
Beegle RD, Brown LM, Weinstein DA (2015) Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. JIMD Rep 18:23–32. https://doi.org/10.1007/8904
Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152:63–70. https://doi.org/10.1007/BF02072092
Brix AE, Howerth EW, Egnor D et al (1995) Glycogen storage disease type Ia in two littermate maltese puppies. Vet Pathol 32:460–465. https://doi.org/10.1177/030098589503200502
Brooks ED, Little D, Arumugam R et al (2013) Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine glycogen storage disease type Ia. Mol Genet Metab 109:161–170. https://doi.org/10.1016/j.ymgme.2013.03.018
Brooks ED, Landau DJ, Everitt JI et al (2018) Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy. J Inherit Metab Dis 41:965–976. https://doi.org/10.1007/s10545-018-0223-y
Calderaro J, Labrune P, Morcrette G et al (2013) Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol 58:350–357. https://doi.org/10.1016/j.jhep.2012.09.030
Cangelosi D, Resaz R, Petretto A et al (2019) A Proteomic analysis of GSD-1a in mouse livers: evidence for metabolic reprogramming, inflammation, and macrophage polarization. J Proteome Res 18:2965–2978. https://doi.org/10.1021/acs.jproteome.9b00309
Cao J, Choi M, Guadagnin E et al (2021) mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat Commun 12:1–14. https://doi.org/10.1038/s41467-021-23318-2
Casteras S, Abdul-Wahed A, Soty M et al (2016) The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice. Diabetologia 59:2645–2653. https://doi.org/10.1007/s00125-016-4097-y
Chandler RJ, La Fave MC, Varshney GK et al (2015) Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Investig 125:870–880. https://doi.org/10.1172/JCI79213
Cho JH, Kim GY, Pan CJ et al (2017) Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia. PLoS Genet 13:1–20. https://doi.org/10.1371/journal.pgen.1006819
Cho J, Kim G, Mansfield BC, Chou JY (2018) Sirtuin signaling controls mitochondrial function in glycogen storage disease type Ia. J Inherit Metab Dis 41:997–1006
Cho JH, Lee YM, Starost MF et al (2019) Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage. J Inherit Metab Dis 42:459–469. https://doi.org/10.1002/jimd.12056
Chou J, Matern D, Mansfield B, Chen Y-T (2002) Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2:121–143. https://doi.org/10.2174/1566524024605798
Clar J, Gri B, Calderaro J et al (2014) Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy. Kidney Int 86:747–756. https://doi.org/10.1038/ki.2014.102
Dambska M, Labrador EB, Kuo CL, Weinstein DA (2017) Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control. Pediatr Diabetes 18:327–331. https://doi.org/10.1111/pedi.12540
Dick J, Kumar N, Horsfield C, Jayawardene S (2012) AA Amyloidosis in a patient with glycogen storage disorder and progressive chronic kidney disease. Clin Kidney J 5:559–561. https://doi.org/10.1093/ckj/sfs143
Farah BL, Landau DJ, Sinha RA et al (2016) Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. J Hepatol 64:370–379. https://doi.org/10.1016/j.jhep.2015.10.008
Farah BL, Sinha RA, Wu Y et al (2017) Hepatic mitochondrial dysfunction is a feature of glycogen storage disease type Ia (GSDIa). Sci Rep 7:1–12. https://doi.org/10.1038/srep44408
Feil R, Brocard J, Mascrez B et al (1996) Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci U S A 93:10887–10890. https://doi.org/10.1073/pnas.93.20.10887
Galluzzi L, Pietrocola F, Levine B, Kroemer G (2014) Metabolic control of autophagy. Cell 159:1263–1276. https://doi.org/10.1016/j.cell.2014.11.006
Gautam S, Zhang L, Arnaoutova I et al (2020) The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia. Hum Mol Genet 29:834–844
Gjorgjieva M, Raffin M, Duchampt A et al (2016) Progressive development of renal cysts in glycogen storage disease type I. Hum Mol Genet 25:3784–3797. https://doi.org/10.1093/hmg/ddw224
Gjorgjieva M, Calderaro J, Monteillet L et al (2018) Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. J Hepatol 69:1074–1087. https://doi.org/10.1016/j.jhep.2018.07.017
Green DR, Galluzzi L, Kroemer G (2011) Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (80-) 333:1109–1112. https://doi.org/10.1126/science.1201940
Greene HL, Slonim AE, O’Neill JA, Burr IM (1976) Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. N Engl J Med 294:423–425. https://doi.org/10.1056/nejm197602192940805
Hariharan N, Maejima Y, Nakae J et al (2010) Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 107:1470–1482. https://doi.org/10.1161/CIRCRESAHA.110.227371
Hoogerland JA, Peeks F, Hijmans BS et al (2021) Impaired very-low-density lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in glycogen storage disease type Ia. J Inherit Metab Dis 44:1–14. https://doi.org/10.1002/jimd.12380
Kang HR, Gjorgjieva M, Smith SN et al (2019a) Pathogenesis of hepatic tumors following gene therapy in murine and canine models of glycogen storage disease. Mol Ther Methods Clin Dev 15:383–391. https://doi.org/10.1016/j.omtm.2019.10.016
Kang HR, Waskowicz L, Seifts AM et al (2019b) Bezafibrate enhances AAV vector-mediated genome editing in glycogen storage disease type Ia. Mol Ther Methods Clin Dev 13:265–273. https://doi.org/10.1016/j.omtm.2019.02.002
Kim SY, Chen LY, Yiu WH et al (2007) Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia. FEBS Lett 581:3833–3838. https://doi.org/10.1016/j.febslet.2007.07.013
Kim SY, Weinstein DA, Starost MF et al (2008) Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia. J Hepatol 48:479–485. https://doi.org/10.1016/j.jhep.2007.11.014
Kim G, Lee YM, Kwon JH et al (2017) Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors. Mol Genet Metab 120:229–234. https://doi.org/10.1016/j.ymgme.2017.01.003
Kishnani PS, Bao Y, Wu JY et al (1997) Isolation and nucleotide sequence of canine glucose-6-phosphatase mRNA: Identification of mutation in puppies with glycogen storage disease type Ia. Biochem Mol Med 61:168–177. https://doi.org/10.1006/bmme.1997.2600
Kishnani PS, Faulkner E, VanCamp S et al (2001) Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia). Vet Pathol 38:83–91. https://doi.org/10.1354/vp.38-1-83
Koeberl DD, Sun BD, Damodaran TV et al (2006) Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. Gene Ther 13:1281–1289. https://doi.org/10.1038/sj.gt.3302774
Koeberl DD, Pinto C, Sun B et al (2008) AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 16:665–672. https://doi.org/10.1038/mt.2008.15
Landau DJ, Brooks ED, Perez-Pinera P et al (2016) In vivo zinc finger nuclease-mediated targeted integration of a glucose-6-phosphatase transgene promotes survival in mice with glycogen storage disease type IA. Mol Ther 24:697–706. https://doi.org/10.1038/mt.2016.35
Lee YM, Jun HS, Pan CJ et al (2012) Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 56:1719–1729. https://doi.org/10.1002/hep.25717
Lee JM, Wagner M, Xiao R et al (2014) Nutrient sensing nuclear receptors coordinate autophagy. Nature 516:112–115. https://doi.org/10.1038/nature13961
Lee YM, Kim GY, Pan CJ et al (2015) Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia. Mol Genet Metab Rep 3:28–32. https://doi.org/10.1016/j.ymgmr.2015.03.001
Lee YM, Conlon TJ, Specht A et al (2018) Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia. J Inherit Metab Dis 41:977–984. https://doi.org/10.1007/s10545-018-0248-2
Lei KJ, Chen YT, Chen H et al (1995) Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet 57:766–771
Lei KJ, Chen H, Pan CJ et al (1996) Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse. Nat Genet 13:203–209. https://doi.org/10.1038/ng0696-203
Lei Y, Hoogerland JA, Bloks VW et al (2020) Hepatic carbohydrate response element binding protein activation limits nonalcoholic fatty liver disease development in a mouse model for glycogen storage disease type 1a. Hepatology 72:1638–1653. https://doi.org/10.1002/hep.31198
Luo X, Hall G, Li S et al (2011) Hepatorenal correction in murine glycogen storage disease type i with a double-stranded adeno-associated virus vector. Mol Ther 19:1961–1970. https://doi.org/10.1038/mt.2011.126
Mihaylova MM, Shaw RJ (2011) The AMP-activated protein kinase (AMPK) signaling pathway coordinates cell growth, autophagy, and metabolism. Nat Cell Biol 13:1016–1023. https://doi.org/10.1038/ncb2329
Monteillet L, Gjorgjieva M, Silva M et al (2018) Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Mol Metab 16:100–115. https://doi.org/10.1016/j.molmet.2018.07.006
Monteillet L, Labrune P, Hochuli M et al (2022) Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy. Hum Mol Genet 31:914–928. https://doi.org/10.1093/hmg/ddab297
Mundy HR, Hindmarsh PC, Matthews DR et al (2003) The regulation of growth in glycogen storage disease type 1. Clin Endocrinol (oxf) 58:332–339. https://doi.org/10.1046/j.1365-2265.2003.01717.x
Mutel E, Abdul-Wahed A, Ramamonjisoa N et al (2011a) Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. J Hepatol 54:529–537. https://doi.org/10.1016/j.jhep.2010.08.014
Mutel E, Gautier-Stein A, Abdul-Wahed A et al (2011b) Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 60:3121–3131. https://doi.org/10.2337/db11-0571
Nault JC, Datta S, Imbeaud S et al (2015) Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47:1187–1193. https://doi.org/10.1038/ng.3389
Ng F, Tang BL (2013) Sirtuins’ modulation of autophagy. J Cell Physiol 228:2262–2270. https://doi.org/10.1002/jcp.24399
Peng WT, Pan CJ, Lee EJ et al (2009) Generation of mice with a conditional allele for G6pc. Genesis 47:590–594. https://doi.org/10.1002/dvg.20538
Penhoat A, Mutel E, Amigo-Correig M et al (2011) Protein-induced satiety is abolished in the absence of intestinal gluconeogenesis. Physiol Behav 105:89–93. https://doi.org/10.1016/j.physbeh.2011.03.012
Poe R, Snover DC (1988) Adenomas in glycogen storage disease type 1 two cases with unusual histologic features. Am J Surg Pathol 12:477–483
Rajas F, Clar J, Gautier-Stein A, Mithieux G (2015) Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease. J Inherit Metab Dis 38:521–527. https://doi.org/10.1007/s10545-014-9761-0
Rajas F, Dentin R, Cannella Miliano A et al (2021) The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice. Mol Metab 43:101108. https://doi.org/10.1016/j.molmet.2020.101108
Rake J, Visser G, Labrune P et al (2002) Glycogen storage disease type I: diagnosis, management, clinical course and outcome. results of the European study on glycogen storage disease type I (ESGSD I). Eur J Pediatr 161:S20–S34. https://doi.org/10.1007/s00431-002-0999-4
Resaz R, Vanni C, Segalerba D et al (2014) Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-aα deficiency. DMM Dis Model Mech 7:1083–1091. https://doi.org/10.1242/dmm.014878
Roseman DS, Khan T, Rajas F et al (2018) G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a. Mol Ther 26:814–821. https://doi.org/10.1016/j.ymthe.2018.01.006
Rutten MGS, Derks TGJ, Huijkman NCA et al (2021) Modeling phenotypic heterogeneity of glycogen storage disease type 1a liver disease in mice by somatic CRISPR/CRISPR-associated protein 9–mediated gene editing. Hepatology 74:2491–2507. https://doi.org/10.1002/hep.32022
Saeed A, Hoogerland JA, Wessel H et al (2020) Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels. Hum Mol Genet 29:264–273. https://doi.org/10.1093/hmg/ddz283
Sun MS, Pan CJ, Shieh JJ et al (2002) Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice. Hum Mol Genet 11:2155–2164. https://doi.org/10.1093/hmg/11.18.2155
Shah KK, O’Dell SD (2013) Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis. J Hum Nutr Diet 26:329–339. https://doi.org/10.1111/jhn.12030
Stoot JHMB, Coelen RJS, De Jong MC, Dejong CHC (2010) Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB 12:509–522. https://doi.org/10.1111/j.1477-2574.2010.00222.x
van Schaftingen E, Gerin I (2002) The glucose-6-phosphatase system. Biochem J 362:513–532. https://doi.org/10.1242/dmm.014878
Waskowicz LR, Zhou J, Landau DL et al (2019) Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia. Hum Mol Genet 28:143–154
Weinstein DA, Correia CE, Conlon T et al (2010) Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum Gene Ther 21:903–910. https://doi.org/10.1089/hum.2009.157
Yavarow ZA, Kang H-R, Waskowicz LR et al (2020) Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. Hum Mol Genet 29:286–294
Yiu WH, Pan C-J, Ruef RA et al (2008) The angiotensin system mediates renal fibrosis in glycogen storage disease type Ia nephropathy. Kidney Int 7323:716–723
Yiu WH, Lee YM, Peng WT et al (2010a) Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol Ther 18:1076–1084. https://doi.org/10.1038/mt.2010.64
Yiu WH, Mead PA, Jun HS et al (2010b) Oxidative stress mediates nephropathy in type Ia glycogen storage disease. Lab Investig 90:620–629. https://doi.org/10.1038/labinvest.2010.38
Zhang L, Lee C, Arnaoutova I et al (2020) Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia. Biochem Biophys Res Commun 527:824–830. https://doi.org/10.1016/j.bbrc.2020.04.124
Zhou J, Waskowicz LR, Lim A et al (2019) A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia. Thyroid 29:1158–1167. https://doi.org/10.1089/thy.2019.0007
Funding
The work was carried out as part of the state assignment from the Ministry of Education and Science of Russia for the Research Centre for Medical Genetics.
Author information
Authors and Affiliations
Contributions
SS presented the idea for the article and critically revised the work. IP performed the literature search and data analysis and drafted the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Petrova, I.O., Smirnikhina, S.A. Studies on glycogen storage disease type 1a animal models: a brief perspective. Transgenic Res 31, 593–606 (2022). https://doi.org/10.1007/s11248-022-00325-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11248-022-00325-7